Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Clearance Models: Physiological Models01:09

Clearance Models: Physiological Models

Drug clearance is a critical pharmacokinetic process involving the irreversible removal of drugs from the body through various organs over a specified time period. Physiological models are indispensable in determining organ-specific clearance, defined by the proportion of the drug eliminated per unit of time from the organ's blood volume.
The organ's clearance rate depends on the blood flow to the organ and the extraction ratio (E). The extraction ratio describes the organ's proficiency in drug...
Clearance Models: Compartment Models01:25

Clearance Models: Compartment Models

Clearance measures drug elimination from the central compartment, including plasma and highly perfused organs like kidneys and liver. Its calculation varies depending on pharmacokinetic models and administration routes. The one-compartment model, for instance, portrays the pharmacokinetics of polar drugs such as aminoglycoside antibiotics administered intravenously and readily excreted in urine. In this case, clearance is influenced by the terminal rate constant (λz) and the total volume of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elimination of myotonia improves myopathy in a muscleblind-like knockout model of myotonic dystrophy.

Nature communications·2026
Same author

A Phase 1 Study of Convection-Enhanced Delivery of Intraputaminal AAV2-GDNF in Advanced Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

AAV-Delivered RNAi Targeting Mutant LDB3 Prevents and Reverses Myofibrillar Myopathy through Mechanosignaling Restoration.

bioRxiv : the preprint server for biology·2026
Same author

WATER reveals heterochrony of molecular programs underlies developmental failure caused by minor spliceosome inhibition.

bioRxiv : the preprint server for biology·2026
Same author

Longitudinal Psychometric Properties of the Myotonic Dystrophy Health Index in a Large Multicenter Cohort of People Living With Myotonic Dystrophy Type 1.

Muscle & nerve·2026
Same author

SHAPE-MaP-Based Assessment of the Structure of Citrus Tristeza Virus Long Non-Coding RNA.

Viruses·2026

Related Experiment Video

Updated: Jul 8, 2026

Tibial Nerve Transection - A Standardized Model for Denervation-induced Skeletal Muscle Atrophy in Mice
10:50

Tibial Nerve Transection - A Standardized Model for Denervation-induced Skeletal Muscle Atrophy in Mice

Published on: November 3, 2013

A muscleblind knockout model for myotonic dystrophy.

Rahul N Kanadia1, Karen A Johnstone, Ami Mankodi

  • 1Department of Molecular Genetics and Microbiology, Powell Gene Therapy Center, Gainesville, FL 32610, USA.

Science (New York, N.Y.)
|December 13, 2003
PubMed
Summary
This summary is machine-generated.

Myotonic dystrophy (DM) arises from repeat expansions. Disrupting the Mbnl1 gene in mice caused DM-like symptoms, supporting the RNA sequestration hypothesis.

More Related Videos

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

Rodent Model of Masseter Volumetric Muscle Loss for Studying Bioengineering Materials
03:46

Rodent Model of Masseter Volumetric Muscle Loss for Studying Bioengineering Materials

Published on: May 31, 2024

Related Experiment Videos

Last Updated: Jul 8, 2026

Tibial Nerve Transection - A Standardized Model for Denervation-induced Skeletal Muscle Atrophy in Mice
10:50

Tibial Nerve Transection - A Standardized Model for Denervation-induced Skeletal Muscle Atrophy in Mice

Published on: November 3, 2013

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

Rodent Model of Masseter Volumetric Muscle Loss for Studying Bioengineering Materials
03:46

Rodent Model of Masseter Volumetric Muscle Loss for Studying Bioengineering Materials

Published on: May 31, 2024

Area of Science:

  • Genetics
  • Molecular Biology
  • Neuromuscular Disorders

Background:

  • Myotonic dystrophy (DM) is a genetic neuromuscular disorder.
  • It is characterized by microsatellite repeat expansions in specific genes.
  • Abnormal RNA transcripts in DM patients sequester RNA-binding proteins, disrupting splicing.

Purpose of the Study:

  • To investigate the role of the muscleblind-like 1 (Mbnl1) gene in DM pathogenesis.
  • To determine if Mbnl1 disruption recapitulates DM disease features.
  • To provide evidence for the RNA sequestration mechanism in DM.

Main Methods:

  • Gene disruption of Mbnl1 in a mouse model.
  • Analysis of muscle, eye, and RNA splicing abnormalities.
  • Comparison of Mbnl1-deficient mouse phenotype with human DM.

Main Results:

  • Mice lacking functional Mbnl1 exhibited muscle and eye abnormalities.
  • RNA splicing defects characteristic of DM were observed in Mbnl1-deficient mice.
  • These findings directly link Mbnl1 to DM pathology.

Conclusions:

  • The Mbnl1 gene is crucial for normal muscle and eye development.
  • Disruption of Mbnl1 leads to a disease phenotype mirroring myotonic dystrophy.
  • Sequestration of Mbnl proteins by mutant RNAs is a key mechanism driving DM.